Evidence map›Paper›PMID 41051704›Full record

ReviewAdvances in neurobiology2025

Pharmacological Mechanisms of SLC6 Neurotransmitter Transporter Inhibition.

Dipanjana Bandyopadhyay, Smruti Ranjan Nayak, Aravind Penmatsa

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dipanjana Bandyopadhyay *Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India.
Smruti Ranjan Nayak *Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India.
Aravind PenmatsaMolecular Biophysics Unit, Indian Institute of Science, Bangalore, India. penmatsa@iisc.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solute carrier 6 family members comprise of neurotransmitter sodium symporters that are the transporters primarily involved in the reuptake of released neurotransmitters from the synaptic space. The family includes structurally related transporters involved in biogenic amine and amino acid neurotransmitter uptake and is a well-known therapeutic target for several classes of inhibitors for the treatment of ailments ranging from depression, pain, addiction, seizures and anxiety. Inhibition of NSS transporters can work either through competitive inhibition or through allosteric inhibition at diverse sites that target multiple conformational states of the transporters. This chapter explores the diverse inhibition strategies observed with numerous inhibitors that target this class of transporters and potential for improvements in inhibition strategies.

Indexed as

Neurotransmitter Transport ProteinsPlasma Membrane Neurotransmitter Transport ProteinsAnimalsHumansNeurotransmitter AgentsNeurotransmitter AgentsNeurotransmitter Transport ProteinsPlasma Membrane Neurotransmitter Transport ProteinsAllosteric inhibitorsCompetitive inhibitionNeurotransmitter sodium symporters (NSS)Reuptake inhibitorsSolute carrier 6 (SLC6)

Identifiers

PMID41051704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.